Katrin Nagl

Dr. Katrin Nagl


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
RCRoque Cardona-Hernandez
Roque Cardona-Hernandez
ASAnke Schwandt
Anke Schwandt
HAHessa Alkandari
Hessa Alkandari
HBHeiko Bratke
Heiko Bratke
Agata ChobotAgata Chobot
Agata Chobot
CJCraig Jefferies
Craig Jefferies
OBJECTIVE Insulin delivery methods, glucose-monitoring modalities, and related outcomes were examined in a large, international, diverse cohort of children and adolescents with type 1 diabetes from the Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) -Registry. RESEARCH DESIGN AND METHODS Participants with type 1 diabetes of ≥1 year, aged ≤18 years, and who had documented pump or sensor usage during the period August 2017–July 2019 were stratified into four categories: injections–no sensor (referent); injections + sensor; pump–no sensor; and pump + sensor. HbA1c and proportion of patients with diabetic ketoacidosis (DKA) or severe hypoglycemia (SH) were analyzed; linear and logistic regression models adjusted for demographics, region, and gross domestic product per capita were applied. RESULTS Data of 25,654 participants were analyzed. The proportions of participants (adjusted HbA1c data) by study group were as follows: injections–no sensor group, 37.44% (8.72; 95% CI 8.68–8.75); injections + sensor group, 14.98% (8.30; 95% CI 8.25–8.35); pump–no sensor group, 17.22% (8.07; 95% CI 8.03–8.12); and pump + sensor group, 30.35% (7.81; 95% CI 7.77–7.84). HbA1c was lower in all categories of participants who used a pump and/or sensor compared with the injections–no sensor treatment method (P < 0.001). The proportion of DKA episodes was lower in participants in the pump + sensor (1.98%; 95% CI 1.64–2.48; P < 0.001) and the pump–no sensor (2.02%; 95% CI 1.64–2.48; P < 0.05) groups when compared with those in the injections–no sensor group (2.91%; 95% CI 2.59–3.31). The proportion of participants experiencing SH was lower in pump–no sensor group (1.10%; 95% CI 0.85–1.43; P < 0.001) but higher in the injections + sensor group (4.25%; 95% CI 3.65–4.95; P < 0.001) compared with the injections–no sensor group (2.35%; 95% CI 2.04–2.71). CONCLUSIONS Lower HbA1c and fewer DKA episodes were observed in participants using either a pump or continuous glucose monitoring (CGM) or both. Pump use was associated with a lower rate of SH. Across SWEET centers, use of pumps and CGM is increasing. The concomitant use of pump and CGM was associated with an additive benefit.

15 July 2016 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
KNKatrin Nagl
Katrin Nagl
JHJulia M. Hermann
Julia M. Hermann
MPMichaela Plamper
Michaela Plamper
CSCarmen Schröder
Carmen Schröder
ADAxel Dost
Axel Dost
RHReinhard W. Holl
Reinhard W. Holl
Insulin dose-adjusted hemoglobin A1c (HbA1C, IDAA1c) correlates well with stimulated C-peptide levels, but has not yet been evaluated in a large cohort of patients with Type 1 diabetes (T1D). We investigated prevalence of partial remission (PREM) defined by IDAA1c ≤9 in 3657 in children with new-onset T1D who were continuously followed over 6 years. We evaluated the predictors of PREM using the multicenter database from the DPV (Diabetes Patienten Verlaufsdokumentation) registry. PREM occurred in 71% of patients. Median duration was 9 (0-21) months. Compared to children <5 years at T1D onset, those aged 5-10 and ≥10 years had twice the chance of developing PREM (OR: 2.08, CI: 1.67-2.60; P < .001 and OR: 2.16, CI: 1.70-2.75; P < .001). Boys were more likely to develop PREM than girls (OR 1.41, CI: 1.18-1.69; P = .0002). Further predictors for PREM were: ketoacidosis, autoantibodies, and HbA1c at T1D onset. These results were confirmed by quantile regression analysis with duration of PREM as dependent variable. This research on a large cohort provides insight into epidemiologic characteristics of PREM in T1D defined by IDAA1c. As IDAA1c does not discriminate between insulin sensitivity and secretion, available data cannot resolve whether the sex-difference in PREM reflects innate higher insulin resistance in girls, or better beta-cell recovery in boys. Further research is needed to clarify the usefulness and performance of IDAA1c in clinical practice.

29 May 2019 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
GMGianluca Musolino
Gianluca Musolino
KDKlemen Dovč
Klemen Dovč
CBCharlotte K. Boughton
Charlotte K. Boughton
MTMartin Tauschmann
Martin Tauschmann
JAJanet M. Allen
Janet M. Allen
OCon behalf of Kidsap Consortium
on behalf of Kidsap Consortium
Objective To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day‐and‐night hybrid closed‐loop insulin delivery. Methods Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed‐loop experience survey following two 3‐week periods of unrestricted day‐and‐night hybrid closed‐loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed‐loop technology were explored. Results Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed‐loop. Ninety percent of the responders felt less worried about their child's glucose control using closed‐loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets. Conclusions Parents/caregivers of very young children reported important quality of life benefits associated with using closed‐loop, supporting adoption of this technology in this population.

20 August 2019 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
KNKatrin Nagl
Katrin Nagl
EBEsther Bollow
Esther Bollow
SLSusanne Liptay
Susanne Liptay
JRJoachim Rosenbauer
Joachim Rosenbauer
SKSibylle Koletzko
Sibylle Koletzko
NPNicole Prinz
Nicole Prinz
Objectives To study celiac‐specific antibody status over three years in patients with type 1 diabetes and biopsy‐proven celiac disease (T1D + CD). Further, to determine clinical differences after diagnosis between patients reaching constant antibody‐negativity (Ab‐neg) and staying antibody‐positive (Ab‐pos). Methods 608 pediatric T1D + CD patients from the multicenter DPV registry were studied longitudinally regarding their CD‐specific antibody‐status. Differences between Ab‐neg (n = 218) and Ab‐pos (n = 158) patients three years after biopsy were assessed and compared with 26 833 T1D patients without CD by linear and logistic regression adjusted for age, gender, diabetes duration and migration background. Results 36% of T1D + CD patients reached and sustained antibody‐negativity three years after CD diagnosis. The median time until patients returned to Ab‐neg was 0.86 (0.51;1.16) years. Three years after diagnosis, HbA1c was lowest in Ab‐neg and highest in Ab‐pos patients compared to T1D‐only patients (adjusted mean (95%CI): 7.72 (7.51‐7.92) % vs 8.44 (8.20‐8.68) % vs 8.19 (8.17‐8.21) %, adjusted P < 0.001, respectively). Total cholesterol, LDL‐cholesterol and frequency of dyslipidemia were significantly lower in Ab‐neg compared to T1D‐only patients (167 (161‐173) mg/dl vs 179 (178‐179) mg/dl, P < 0.001; 90 (84‐96) mg/dl vs 99 (98‐99) mg/dl, P = 0.005; 15.7 (10.5‐22.9)% vs 25.9 (25.2‐26.6)%, P = 0.017). In longitudinal analyses over six years after diagnosis, a constantly higher HbA1c (P < 0.001) and a lower height‐SDS (P = 0.044) was observed in Ab‐pos compared to Ab‐neg patients. Conclusion Only one third of T1D + CD‐patients reached constant Ab‐negativity after CD‐diagnosis. Achieving Ab‐negativity after diagnosis seems to be associated with better metabolic control and growth, supposedly due to a higher adherence to therapy in general.

22 September 2022 in Pediatric Diabetes
Verified
Journal Article
Open access
NBNataša Bratina
Nataša Bratina
MAMarie Auzanneau
Marie Auzanneau
NBNiels Birkebæk
Niels Birkebæk
CBCarine de Beaufort
Carine de Beaufort
Valentino CherubiniValentino Cherubini
Valentino Cherubini
KDKim C. Donaghue
Kim C. Donaghue
To examine the prevalence, time trends, and risk factors of diabetic retinopathy (DR) among youth with type 1 diabetes (T1D) from 11 countries (Australia, Austria, Denmark, England, Germany, Italy, Luxemburg, Netherlands, Slovenia, United States, and Wales). Data on individuals aged 10–21 years with T1D for >1 year during the period 2000–2020 were analyzed. We used a cross‐sectional design using the most recent year of visit to investigate the time trend. For datasets with longitudinal data, we aggregated the variables per participant and observational year, using data of the most recent year to take the longest observation period into account. DR screening was performed through quality assured national screening programs. Multiple logistic regression models adjusted for the year of the eye examination, age, gender, minority status, and duration of T1D were used to evaluate clinical characteristics and the risk of DR. Data from 156,090 individuals (47.1% female, median age 15.7 years, median duration of diabetes 5.2 years) were included. Overall, the unadjusted prevalence of any DR was 5.8%, varying from 0.0% (0/276) to 16.2% between countries. The probability of DR increased with longer disease duration (aORper‐1‐year‐increase = 1.04, 95% CI: 1.03–1.04, p < 0.0001), and decreased over time (aORper‐1‐year‐increase = 0.99, 95% CI: 0.98–1.00, p = 0.0093). Evaluating possible modifiable risk factors in the exploratory analysis, the probability of DR increased with higher HbA1c (aORper‐1‐mmol/mol‐increase‐in‐HbA1c = 1.03, 95% CI: 1.03–1.03, p < 0.0001) and was higher among individuals with hypertension (aOR = 1.24, 95% CI: 1.11–1.38, p < 0.0001) and smokers (aOR = 1.30, 95% CI: 1.17–1.44, p < 0.0001). The prevalence of DR in this large cohort of youth with T1D varied among countries, increased with diabetes duration, decreased over time, and was associated with higher HbA1c, hypertension, and smoking.

21 November 2020 in Pediatric Diabetes
Verified
Journal Article
Open access
PDF file
KNKatrin Nagl
Katrin Nagl
GBGabriele Berger
Gabriele Berger
FAFelix Aberer
Felix Aberer
HZHaris Ziko
Haris Ziko
KWKatharina Weimann
Katharina Weimann
Julia MaderJulia Mader
Julia Mader
Aim The aim of this study was to assess accuracy of the three most commonly used continuous glucose monitoring (CGM) systems in almost real‐life situation during a diabetes camp in children with type 1 diabetes (T1D) aged 9‐14 years. Methods Data was gathered during a 2‐week summer camp under physicians’ supervision. Out of 38 participating children with T1D (aged: 11.0 [9.9; 12.1] years; 57% girls, mean HbA1c 7.2 [6.9; 7.7] %,) 37 wore a CGM system (either Abbott FreeStyle Libre (FSL), Dexcom G6 (DEX) or Medtronic Enlite (ENL)) throughout the camp. All concomitantly available data pairs of capillary glucose measurements and sensor values were used for the analysis. Mean absolute relative difference (MARD) was calculated and Parkes Error Grid analyses were done for all three systems used. Results In total 2,079 data pairs were available for analysis. The overall MARDs of CGM systems used at the camp was FSL: 13.3% (6.7;21.6). DEX: 10.3% (5.8; 16.7) and ENL 8.5% (3.6; 15.6). During eu‐, hypo‐ and hyperglycemia MARDs were lowest in ENL. Highest MARDs were seen in hypoglycemia, where all three systems exhibited MARDs above 15%. Overnight MARDs of all systems was higher than during day‐time. Conclusion All sensors performed worst in hypoglycemia. Performance of the adequately calibrated Medtronic system outperformed the factory‐calibrated sensors. For clinical practice, it is important to adequately train children with T1D and families in the correct procedures for sensors that require calibrations.